Muscular Dystrophy – Review
DOI:
https://doi.org/10.61841/7dcqzy67Keywords:
Muscular Dystrophy, Duchenne Muscular Dystrophy,, , Exondys 51.Abstract
Muscular dystrophy is a group of genetic disorders that result in progressive loss of muscle mass and weakness. This condition results from mutation in dystrophin gene that results in synthesis of abnormal dystrophin protein leading to formation of damaged muscles. Duchenne muscular dystrophy is the most common form of Muscular Dystrophy. Most people end up in wheelchair as the muscles become weaker progressively. At present there is no treatment for this inherited diseased condition. Medications available are generally prescribed to give symptomatic relief. However, with the advancement in technology, scientists all over the world are researching for a therapy that might help people suffering from this disease by either reversing the disease or completely curing it. Of the approaches available, exon skipping, stem cell transplant are some of the areas that are being explored. This article gives a brief about the condition of muscular dystrophy, its types, causes, treatment and research area along with clinical trials that are being run for the condition.
Downloads
References
[1] Alan E H Emery. The muscular dystrophies. BMJ. vol 317,pp 991–995,1998
[2] Kriston Wilson .Duchenne and Becker muscular dystrophies: a review of animal models, clinical endpoints, and biomarker quantification. Toxicol Pathol. Vol. 45(7), 961–976,Oct 2017.
[3] E C Ingrid.Verhaart, A R Annemieke. Therapeutic developments for Duchenne muscular dystrophy.
Nature Reviews Neurology. vol. 15, pp. 373–386,2019.
[4] Eppie M Yiu Andrew J Kornberg. Duchenne muscular dystrophy. Journal of Paediatrics and Child Health. Vol. 51(8),pp.759-764, Aug 2015.
[5] Carlos Pascual Morena.. Effectiveness of pharmacological treatments in Duchenne muscular dystrophy: a protocol for a systematic review and meta-analysis. Neurology. BMJ. vol., 9 (9), 2019.
[6] Miura P .Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?.
Trends Mol Med, vol. 12(3),pp. 122-9, Mar 2006.
[7] Daniel Skuk.Clarifying Misconceptions About Myoblast Transplantation in Myology. Mol Ther, vol., 22(5),pp. 897–898, May2014.
[8] Rodino-Klapac LR .Gene therapy for duchenne muscular dystrophy: expectations and challenges. Arch Neurol. Vol. 64(9), pp. 1236-41. Sep 2007.
[9] Sara Martina Maffioletti. Stem Cell Transplantation for Muscular Dystrophy: The Challenge of Immune Response. Biomed Res Int. 964010, 2014.
[10] Rosamund C. Smith. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. CurrOpin Support Palliat Care. vol. 7(4),pp.352–360, Nov 2013.
[11] Maria De Los Angeles Beytía.Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol. Vol. 31(1),pp. 4–8, May 2012.
[12] Prof David J Birnkrant .Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. vol. 17(3),pp. 251–267, Mar 2018 .
[13] Satish V. Khadilkar .Limb-girdle Muscular Dystrophies in India: A Review. Ann Indian Acad Neurol.vol.
20(2),pp. 87–95, Apr-Jun 2017.
[14] Miceli MC, Nelson SF. The case for eteplirsen: Paving the way for precision medicine. Mol Genet Metab.vol. 118(2),pp.70-1,Jun 2016.
[15] Kole R, Krieg AM: Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015 Jun 29;87:104-7
[16] Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM: Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. vol.74(5),pp. 637-47, Nov 2013.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
